

Product safety study for a citrate calcium anticoagulation system

Submission date 04/02/2009	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
Registration date 27/02/2009	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 27/02/2009	Condition category Urological and Genital Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Dieter Falkenhagen

Contact details
Dr.-Karl-Dorrek-Str. 30
Krems
Austria
3500

Additional identifiers

Protocol serial number
N/A

Study information

Scientific Title
Product safety study for a citrate calcium anticoagulation system: an interventional single-arm open-label trial

Study objectives
Primary goal of the study is the proof of functionality and safety of a algorithm for automated software controlled citrate-calcium anticoagulation. The hypothesis of the authors is that the

specification of a target calcium value in the anticoagulated extracorporeal circuit is associated with a high functionality and a high safety using a citrate calcium anticoagulation.

Ethics approval required

Old ethics approval format

Ethics approval(s)

To be submitted to the Ethics Committee of Upper Austria, Wagner Jauregg Mental Health Hospital as of 04/02/2009.

Study design

Interventional single-arm open-label trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Chronic dialysis

Interventions

Regional anticoagulation with trisodium citrate and substitution with calcium chloride. Five treatments per patient over 2 weeks, with a duration of 4 hours per treatment planned.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

The following will be assessed at baseline, after 15 minutes and then every 60 minutes during treatment (maximum treatment duration is 4 hours):

1. Evaluation of the effectiveness of anticoagulation based on coagulation parameters
2. Time dependency of citrate and calcium values in the extracorporeal circuit
3. Anticoagulation state in the extracorporeal circuit
4. Citrate and calcium level in the patients blood

Key secondary outcome(s)

The following will be assessed at baseline and end of each treatment period: D-Dimer, Mg²⁺ and sodium concentration

Completion date

31/08/2009

Eligibility

Key inclusion criteria

1. Both males and females, age: 19 to 65 years
2. Chronic dialysis patients
3. Haematocrit (Hkt): 30 bis 45 %
4. Ca²⁺: 1.0-1.30 mmol/l
5. Weight: >60 kg

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. High risk of bleeding, platelets count <40,000/ μ l
2. Haemoglobin <9 g/dl
3. Alkalosis pH >7.50
4. Acidosis pH <7.35
5. Liver insufficiency
6. Respiratory insufficiency
7. Patients with cardiovascular problems
8. Oral anticoagulans
9. Hepatitis C, B, HIV patients

Date of first enrolment

01/05/2009

Date of final enrolment

31/08/2009

Locations**Countries of recruitment**

Austria

Study participating centre

Dr.-Karl-Dorrek-Str. 30

Krems

Austria

3500

Sponsor information

Organisation

Danube University Krems (Austria)

ROR

<https://ror.org/03ef4a036>

Funder(s)**Funder type**

University/education

Funder Name

Danube University Krems (Austria)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration